Cargando…
The assessment of in vivo somatic mutations in survivors of childhood malignancy.
The assessment of chromosomal mutations in children may provide information about aetiology and risk of second malignancies. A somatic cell mutation assay which determines variant erythrocytes lacking expression of an allelic form of the sialoglycoprotein, glycophorin A, was applied to samples from...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977881/ https://www.ncbi.nlm.nih.gov/pubmed/1637665 |
_version_ | 1782135357239721984 |
---|---|
author | Hewitt, M. Mott, M. G. |
author_facet | Hewitt, M. Mott, M. G. |
author_sort | Hewitt, M. |
collection | PubMed |
description | The assessment of chromosomal mutations in children may provide information about aetiology and risk of second malignancies. A somatic cell mutation assay which determines variant erythrocytes lacking expression of an allelic form of the sialoglycoprotein, glycophorin A, was applied to samples from children before and after receiving potentially genotoxic therapy. Fifty-six children who had received treatment for their malignancy, 15 with malignancy but prior to treatment and 43 control children were assessed for the presence of Nø and NN mutant variant red cells. Control children had mean (s.d.) Nø and NN variant frequencies (Vf) of 9.5 (7.0) and 5.8 (3.3) x 10(6) erythrocytes respectively. Comparison between pre-treatment and control groups demonstrated that prior to chemotherapy, patients with paediatric malignancy do not have mutant frequencies significantly different from the normal population. Children who had received chemotherapy, with or without radiotherapy, showed a significant elevation of both Nø and NN variants over 10 years from the end of treatment. Exposure of children to radiotherapy or known chemical mutagens leads to an increased frequency of variant erythrocytes which is probably the result of in vivo somatic cell mutations. The long term implications have yet to be determined. |
format | Text |
id | pubmed-1977881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1992 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19778812009-09-10 The assessment of in vivo somatic mutations in survivors of childhood malignancy. Hewitt, M. Mott, M. G. Br J Cancer Research Article The assessment of chromosomal mutations in children may provide information about aetiology and risk of second malignancies. A somatic cell mutation assay which determines variant erythrocytes lacking expression of an allelic form of the sialoglycoprotein, glycophorin A, was applied to samples from children before and after receiving potentially genotoxic therapy. Fifty-six children who had received treatment for their malignancy, 15 with malignancy but prior to treatment and 43 control children were assessed for the presence of Nø and NN mutant variant red cells. Control children had mean (s.d.) Nø and NN variant frequencies (Vf) of 9.5 (7.0) and 5.8 (3.3) x 10(6) erythrocytes respectively. Comparison between pre-treatment and control groups demonstrated that prior to chemotherapy, patients with paediatric malignancy do not have mutant frequencies significantly different from the normal population. Children who had received chemotherapy, with or without radiotherapy, showed a significant elevation of both Nø and NN variants over 10 years from the end of treatment. Exposure of children to radiotherapy or known chemical mutagens leads to an increased frequency of variant erythrocytes which is probably the result of in vivo somatic cell mutations. The long term implications have yet to be determined. Nature Publishing Group 1992-07 /pmc/articles/PMC1977881/ /pubmed/1637665 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Hewitt, M. Mott, M. G. The assessment of in vivo somatic mutations in survivors of childhood malignancy. |
title | The assessment of in vivo somatic mutations in survivors of childhood malignancy. |
title_full | The assessment of in vivo somatic mutations in survivors of childhood malignancy. |
title_fullStr | The assessment of in vivo somatic mutations in survivors of childhood malignancy. |
title_full_unstemmed | The assessment of in vivo somatic mutations in survivors of childhood malignancy. |
title_short | The assessment of in vivo somatic mutations in survivors of childhood malignancy. |
title_sort | assessment of in vivo somatic mutations in survivors of childhood malignancy. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977881/ https://www.ncbi.nlm.nih.gov/pubmed/1637665 |
work_keys_str_mv | AT hewittm theassessmentofinvivosomaticmutationsinsurvivorsofchildhoodmalignancy AT mottmg theassessmentofinvivosomaticmutationsinsurvivorsofchildhoodmalignancy AT hewittm assessmentofinvivosomaticmutationsinsurvivorsofchildhoodmalignancy AT mottmg assessmentofinvivosomaticmutationsinsurvivorsofchildhoodmalignancy |